Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
复制标题
DOI：
10.1016/j.jhep.2014.05.044
复制
发表时间：
2014-10-01
影响因子：
25.7
通讯作者：
Zhao, Mianzhi
中科院分区：
文献类型：
--
作者：
Ning, Qin;Han, Meifang;Zhao, Mianzhi
背景8,2目的：在接受核苷类似物治疗的慢性乙型肝炎（CHB）患者中，持续的治疗后反应并不常见。评估了从长期恩替卡韦（ETV）转为聚乙二醇干扰素α -2a的患者的反应、反应预测因素和安全性。方法：乙型肝炎e抗原（HBeAg）阳性CHB患者接受ETV治疗9-36个月，HBeAg
Background 8,2 Aims: Durable post-treatment response is uncommon in chronic hepatitis B (CHB) patients on nucleos(t)ide analogue therapy. Response, response predictors and safety were assessed in patients who switched from long-term entecavir (ETV) to peginterferon alfa-2a.Methods: Hepatitis B e antigen (HBeAg)-positive CHB patients who had received ETV for 9-36 months, with HBeAg